Prescription of GLP-1 receptor agonists and iSGLT2 in geriatrics, is there a risk?

The use of GLP-1 receptor agonists and iSGLT2 is becoming increasingly common, in line with new guidelines issued by the learned societies of cardiology, nephrology and diabetology. However, the enthusiasm aroused by these new drugs needs to be tempered and their use in the very elderly and/or frail...

Full description

Saved in:
Bibliographic Details
Published inRevue médicale suisse Vol. 20; no. 893; p. 1983
Main Authors Moro, Davide, Jean, Michèle, Coutaz, Martial
Format Journal Article
LanguageFrench
Published Switzerland 30.10.2024
Subjects
Aged
Diabetes Mellitus, Type 2 - drug therapy
Geriatric Assessment - methods
Geriatrics - methods
Glucagon-Like Peptide-1 Receptor - agonists
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Practice Guidelines as Topic
Online AccessGet full text

Cover

More Information
Summary:The use of GLP-1 receptor agonists and iSGLT2 is becoming increasingly common, in line with new guidelines issued by the learned societies of cardiology, nephrology and diabetology. However, the enthusiasm aroused by these new drugs needs to be tempered and their use in the very elderly and/or frail needs to be carefully considered by the lack of scientific studies in this population category, , and their prescription requires a comprehensive geriatric assessment before initiating this type of treatment.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1660-9379
DOI:10.53738/REVMED.2024.20.893.1983